Intellia Therapeutics
NTLA
335 hedge funds and large institutions have $10B invested in Intellia Therapeutics in 2021 Q2 according to their latest regulatory filings, with 95 funds opening new positions, 89 increasing their positions, 113 reducing their positions, and 20 closing their positions.
375% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 20
98% more capital invested
Capital invested by funds: $5.06B → $10B (+$4.95B)
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
37% more call options, than puts
Call options by funds: $461M | Put options by funds: $335M
29% more funds holding
Funds holding: 260 → 335 (+75)
1.89% less ownership
Funds ownership: 93.31% → 91.42% (-1.9%)
21% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 113
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$145M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$123M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$75.9M |
| 4 |
DVF
Discovery Value Fund
Singapore
|
+$61M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$36.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$150M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$139M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$131M |
| 4 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$85.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$42.7M |
NTLA Hedge Fund Activity: Q2 2021 in Review
335 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2021, worth a combined $10B — up 98% from $5.06B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new NTLA positions and 20 closed out — a net gain of 75 holders — while 89 added to existing stakes and 113 trimmed.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $145M. The largest seller was ARK Investment Management, cutting an estimated $150M.
- 335 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2021, up from 260 in Q1 2021.
- Funds reported $10B of Intellia Therapeutics stock for Q2 2021, up 98% quarter-over-quarter.
- 95 funds opened new Intellia Therapeutics positions in Q2 2021 and 20 closed out, a net change of +75 holders.
- The largest Intellia Therapeutics buyer in Q2 2021 was Darwin Global Management, an estimated $145M added.
- The largest Intellia Therapeutics seller in Q2 2021 was ARK Investment Management, an estimated $150M sold.
Based on aggregated 13F filings for Q2 2021.